The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Roberto Contieri
Quality of life in patients on active surveillance for bladder cancer
No abstract is available for this article. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References 1, , et al. Deintensification of treatment for low-grade bladder tumors: a collaborative review by the international bladder cancer group (IBCG). Eur Urol Oncol 2025; 8: 179–189 2, , et al. Patient and context factors in the adoption of active surveillance for low-risk prostate cancer.
Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic review
Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the present study. Supporting Information Filename Description bju70404-sup-0001-Supinfo.docxWord 2007 document , 28.8 KB Appendix S1. Literature search strategy. Appendix S2. Excluded articles following full-text review. Table S1. The PRISMA checklist. Table S2. Risk of Bias assessment (PROBAST). References 1, , et al.
Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice
cCR clinical complete response CT computed tomography ctDNA circulating tumour DNA EORTC European Organisation for Research and Treatment of Cancer FDG-PET/CT fluorodeoxyglucose positron emission tomography/computed tomography MIBC muscle-invasive bladder cancer MRI magnetic resonance imaging NAC neoadjuvant chemotherapy nacVI-RADS post-neoadjuvant chemotherapy Vesical Imaging-Reporting and Data System NAT neoadjuvant therapy RC radical cystectomy RCT randomised controlled trial TNM tumour,...
Oncological Outcomes of Radical Nephroureterectomy With or Without Lymphadenectomy and Neoadjuvant Therapy in cN+ UTUC: Insights from the ROBUUST registry.
Get full text access Log in, subscribe or purchase for full access. 8. Bibliography 1. Raman, J.D. ∙ Messer, J. ∙ Sielatycki, J.A. ... Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005 BJU Int. apr. 2011; 107(7):1059-1064 2. Lughezzani, G. ... A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma Urology. gen. 2010; 75(1):118-124 3. Dominguez-Escrig, J.L. ...
Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non–muscle-invasive Bladder Cancer Recurrent High-risk NMIBC: One Bladder, Choose Wisely
Get full text access Log in, subscribe or purchase for full access. References 1. Gore, J.L. ∙ Wolff, E.M. ∙ Nash, M.G. ... Twelve-month results from the CISTO study comparing radical cystectomy versus bladder-sparing therapy for recurrent high-grade non-muscle-invasive bladder cancer J Clin Oncol. 2026; 44:274-285 2. Clements, M.B. ∙ Atkinson, T.M. ∙ Dalbagni, G.M. ... Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort Eur Urol.
Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis
Abstract Xpert Bladder Cancer (BC) is an mRNA-based urine assay for diagnosis and surveillance of urothelial carcinoma. Although previous meta-analyses have examined Xpert, none has evaluated its accuracy in both BC detection and non-muscle-invasive bladder cancer (NMIBC) surveillance, while also exploring its potential role in guiding repeat transurethral resection (re-TURBT) and in the diagnostic evaluation of upper tract urothelial carcinoma (UTUC).
Get full text access Log in, subscribe or purchase for full access. References 1. Shore, N.D. ∙ Powles, T.B. ∙ Bedke, J. ... Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial Nat Med. 2025; 31:2806-2814 2. De Santis, M. ∙ Palou Redorta, J. ∙ Nishiyama, H. ... Durvalumab in combination with BCG for BCG-naive, high-risk, non–muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial Lancet.
Active surveillance in low-grade NMIBC — results of an international two-round modified Delphi consensus
|
By Roberto Contieri, Paolo Gontero, Rodolfo Hurle, Luca Afferi, Simone Albisinni, Marek Babjuk, Alison Birtle, Peter Black, Maurizio Brausi, Otakar Capoun, Albert Carrion, James Catto, Ananya Choudhury, Alessia Cimadamore, Eva M. Compérat, Siamak Daneshmand, David D’Andrea, Francesco Del Giudice, Patrick J. Hensley, Wojciech W. Krajewski, Ekaterina Laukhtina, Roger Li, Fredrik Liedberg, Yair Lotan, Gautier Marcq, Paramananthan Mariappan, Andrea Mari Verified, Alberto Martini, Richard P. Meijer, Maria Carmen Mir, Keiichiro Mori, Marco Moschini, Hugh Mostafid, Joan Palou, Valeria Panebianco, Sisto Perdonà, Sima Porten, Sarah P. Psutka, Michael Rink, Morgan Rouprêt, Thomas Seisen, Mark Soloway, Viktor Soukup, Gary D. Steinberg, Arnulf Stenzl, Karl H. Tully, Toine Van der Heijden, Toine van der Heijden, Bas W. G. van Rhijn, Alfred Witjes, Evanguelos Xylinas, Ashish M. Kamat, Benjamin Pradere, Laura Mertens, Max Bruins, Alexandra Masson Lecomte, Micheal O’Donnell, Jeremy YC Teoh
|
Nature
Verified
Abstract Standard management for recurrent low-grade non-muscle-invasive bladder cancer (LG-NMIBC) often involves a substantial treatment burden, which is not justified by the relatively indolent course of the disease, prompting a need for de-intensification strategies. Active surveillance (AS) is an alternative approach aimed at reducing overtreatment in selected patients.
Re: Hiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019
We read with great interest the report on the JCOG1019 randomized phase 3 trial by Kitamura et al. [1]. The trial evaluated the noninferiority of “active surveillance” in comparison to intravesical bacillus Calmette-Guérin (BCG) induction therapy in patients with high-grade (HG) T1 bladder cancer without residual disease at second transurethral resection of the bladder (TURB).
Refining BCG-failure classifications in non-muscle-invasive bladder cancer
CIS carcinoma in situ CSM cancer-specific mortality EAU-YAU European Association of Urology-Young Academic Urologists HG high grade (s)HR (subdistribution) hazard ratio IBCG International Bladder Cancer Group IQR interquartile range NMIBC non-muscle-invasive bladder cancer OM overall mortality OS overall survival PFS progression-free survival RC radical cystectomy RFS recurrence-free survival (re-)TURBT (repeat) transurethral resection of bladder tumour Introduction Intravesical BCG therapy...
Analysis of Four-Tier Hybrid Grading System for Ta Non-Muscle-Invasive Bladder Cancer - Roberto Contieri
Read the Full Video Transcript Ashish Kamat: Hello everybody and welcome once again to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, urological oncologist in Houston, Texas, and it's a pleasure to welcome once again to our forum Dr. Roberto Contieri, who has been with us several times before. Welcome Roberto. Roberto Contieri: Hi. Thanks for the invitation, and thanks also to UroToday for having me here. Ashish Kamat: So you've talked about different things in the past.
Defining standards for retroperitoneal single-port (SP) robotic surgery: the Advancing Retroperitoneal International SP Excellence (ARISE) international Delphi consensus
ACCORD ACcurate COnsensus Reporting Document (guidelines) ARISE Advancing Retroperitoneal International SP Excellence LAA lower anterior access MP multi-port (RA)PN (robot-assisted) partial nephrectomy RANU robot-assisted nephroureterectomy SP single port Introduction Despite more than two decades of evidence supporting its safety and efficacy, the retroperitoneal approach for robotic renal surgery remains unpopular with most procedures still being performed transperitoneally [1].
Germline Testing for Risk Stratification in Low-Grade Bladder Cancer on Active Surveillance - Roberto Contieri
Read the Full Video Transcript Ashish Kamat: A warm welcome to all of you from the UroToday Studios. I'm Ashish Kamat, Professor of Urologic Oncology at MD Anderson Cancer Center in Houston, Texas. We are live at GU ASCO 25 in San Francisco. And it's a pleasure to welcome to our studios, Dr. Roberto Contieri. Welcome, Roberto. Roberto Contieri: Well, thank you very much for the introductions, Dr. Kamat. Ashish Kamat: So you've been with us before.
Re: Characterizing Psychological Resources and Resilience in Patients with Bladder Cancer: Associations with Frailty and Quality of Life
Also available on ScienceDirect Copyright: © 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Staging Accuracy and Prognostic Value of Prostate-Specific Membrane Antigen PET/CT Strongly Depends on Lymph Node Tumor Burden
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
BACKGROUND: Data for bladder-sparing treatment (BST) in bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) patients report short-term outcomes limited to 1-2 yr. OBJECTIVE: To assess long-term survival outcomes of BCG-unresponsive NMIBC patients treated with BST. DESIGN SETTING AND PARTICIPANTS: BCG-unresponsive NMIBC patients diagnosed between January 2000 and September 2021 from an institutional NMIBC registry were evaluated.
Assessing long‐term upgrade risks in recurrent low‐grade non‐muscle‐invasive bladder cancer, can we deintensify the treatment?
Research Letter Assessing long-term upgrade risks in recurrent low-grade non-muscle-invasive bladder cancer, can we deintensify the treatment?
The International Bladder Cancer Group Intermediate-Risk Non-muscle Invasive Bladder Cancer Scoring System Predicts the Need for Intervention for Patients on Active Surveillance
BACKGROUND AND AIMS Patients with low-grade (LG) Ta non-muscle invasive bladder cancer (NMIBC) exhibit a high recurrence rate, while cancer-specific mortality remains notably low.1 Consequently, preserving patient quality of life through treatment deintensification emerges as a critical objective, simultaneously ensuring a minimal risk of progression to muscle-invasive bladder cancer.
Variation in Follow-Up after Radical Cystectomy for Bladder Cancer-An Inventory Roundtable and Literature Review
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy
References 1, , et al. European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2022; 81: 75–94 2, , et al. Prognostic factors and risk groups in T1G3 non–muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol 2015; 67: 74–82 3, , et al.
Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette-Guérin
Abstract Objective To evaluate the impact of age on oncological outcomes in a large contemporary cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adequate Bacillus Calmette–Guérin (BCG). Patients and Methods We performed an Institutional Review Board-approved retrospective study analysing patients with NMIBC treated with adequate BCG at our institution from 2000 to 2020.
Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review
Abstract : MicroRNAs (miRNAs) are emerging as biomarkers for the detection and prognosis of cancers due to their inherent stability and resilience.
Inflammatory Markers and Type 2 Diabetes as Prognostic Risk Factors in Low‐Risk Bladder Cancer
Research Letter This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1111/bju.16026.
Cancers | Free Full-Text | Evaluating the Protective Effect of Intravesical Bacillus Calmette-Guerin against SARS-CoV-2 in Non-Muscle Invasive Bladder Cancer Patients: A Multicenter Observational Trial
Open AccessArticle by Rodolfo Hurle 1, Francesco Soria 2, Roberto Contieri 1,3, Pier Paolo Avolio 1,3, Stefano Mancon 1,3, Massimo Lazzeri 1,*, Valentina Bernasconi 2, Simone Mazzoli 2, Giuseppe Pizzuto 2, Matteo De Bellis 2, Matteo Rosazza 2, Simone Livoti 2, Tommaso Lupia 4, Silvia Corcione 4, Beatrice Lillaz 2, Francesco Giuseppe De Rosa 4, Nicolò Maria Buffi 1,3, Ashish M.
Cancers | Free Full-Text | Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle by Marina Valeri 1,2, Roberto Contieri 2,3, Vittorio Fasulo 2,3, Martina Iuzzolino 1,2, Miriam Cieri 1,2, Grazia M. Elefante 1, Camilla De Carlo 1,2, Alessandra Bressan 1,2, Cesare Saitta 2,3, Andrea Gobbo 2,3, Pier Paolo Avolio 2,3, Valerio Dacrema 4, Massimo Lazzeri 3, Gianluigi Taverna 5, Luigi M.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Roberto
Contact Roberto, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack